Kumar Prabhash News Today

Vandana Gupta: A recent study by consultancy firm PricewaterhouseCoopers said India has an overall clinical trial participation of approximately 3 per cent. About a decade back, clinical trials were growing rapidly in India but reports emerged of patients not being educated about the trial goals, the medication or their side-effects.

In a first, study documents improved patient outcomes with low dose

Bangalore (Karnataka) [India], August 18 (ANI/NewsVoir): 4baseCare, a precision oncology company in India, launched their product - TARGT Indiegene, India's largest and first population-specific tumour gene panel derived from Whole Exome and Whole Transcriptome data of over 1,500 cancer patients across 28 different cancer types. Most of the patients were presented with stage III/IV disease, and presented with disease progression and had exhausted all the options in the standard of care.

Study: Lung squamous patients harboring druggable mutations have lower median overall survival Oncotarget published " Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations" which reported that unlike lung adenocarcinoma patients, there is no FDA-approved targeted-therapy likely to benefit lung squamous cell carcinoma patients. The authors performed survival analyses of lung squamous cell carcinoma patients harboring therapeutically releva...

Lung cancer is the leading cause of cancer-related deaths across the globe with more than 1.7 million deaths annually.

4baseCare, Tata Memorial Centre to develop AI based clinical interpretation platform 4baseCare, Tata Memorial Centre to develop AI based clinical interpretation platform 09 January 2021 | News This AI driven tool will support oncologist in clinical decision making and to offer precision medicine to cancer patients Image credit- shutterstock.com 4baseCare, an Illumina Accelerator backed precision oncology startup in Bengaluru and ACTREC (Advanced Centre for Treatment, Research and Educa...